Plasma Heme Oxygenase-1 Levels Distinguish Latent or Successfully Treated Human Tuberculosis from Active Disease

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Andrade, Bruno B ^a   Pavan Kumar, Nathella ^a   Mayer Barber, Katrin D ^a   Barber, Daniel L ^a   Sridhar, Rathinam ^b   Rekha, Vaithilingam V Banu ^c   Jawahar, Mohideen S ^c   Nutman, Thomas B ^a   Sher, Alan ^a   Babu, Subash ^a,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Government Stanley Hospital   (India)

^c NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; HEME OXYGENASE 1; INTERLEUKIN 10; INTERLEUKIN 17; SERUM AMYLOID A; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; INDIA; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; SPUTUM CULTURE; SPUTUM SMEAR; TUBERCULOSIS;

ACUTE-PHASE REACTION; ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEME OXYGENASE-1; HUMANS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; ROC CURVE; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84877093611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062618     Document Type: Article

References (32)

1. Davies PD, Pai M, (2008) The diagnosis and misdiagnosis of tuberculosis. Int J Tuberc Lung Dis 12: 1226-1234.
2. Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, et al. (2011) Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb) 91: 250-256.
3. Pai M, Menzies D, (2007) Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis? Clin Infect Dis 44: 74-77.
4. Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, et al. (2000) Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 4: 931-939.
5. Madebo T, Lindtjorn B, Aukrust P, Berge RK, (2003) Circulating antioxidants and lipid peroxidation products in untreated tuberculosis patients in Ethiopia. Am J Clin Nutr 78: 117-122.
6. Tenhunen R, Marver HS, Schmid R, (1968) The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A 61: 748-755.
7. Gozzelino R, Jeney V, Soares MP, (2010) Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 50: 323-354.
8. Morse D, Choi AM, (2005) Heme oxygenase-1: from bench to bedside. Am J Respir Crit Care Med 172: 660-670.
9. Mendonca VR, Luz NF, Santos NJ, Borges VM, Goncalves MS, et al. (2012) Association between the haptoglobin and heme oxygenase 1 genetic profiles and soluble CD163 in susceptibility to and severity of human malaria. Infect Immun 80: 1445-1454.
10. Luz NF, Andrade BB, Feijo DF, Araujo-Santos T, Carvalho GQ, et al. (2012) Heme oxygenase-1 promotes the persistence of Leishmania chagasi infection. J Immunol 188: 4460-4467.
11. Saukkonen K, Lakkisto P, Kaunisto MA, Varpula M, Voipio-Pulkki LM, et al. (2010) Heme oxygenase 1 polymorphisms and plasma concentrations in critically ill patients. Shock 34: 558-564.
12. Kumar A, Deshane JS, Crossman DK, Bolisetty S, Yan BS, et al. (2008) Heme oxygenase-1-derived carbon monoxide induces the Mycobacterium tuberculosis dormancy regulon. J Biol Chem 283: 18032-18039.
13. Shiloh MU, Manzanillo P, Cox JS, (2008) Mycobacterium tuberculosis senses host-derived carbon monoxide during macrophage infection. Cell Host Microbe 3: 323-330.
14. Regev D, Surolia R, Karki S, Zolak J, Montes-Worboys A, et al. (2012) Heme oxygenase-1 promotes granuloma development and protects against dissemination of mycobacteria. Lab Invest 92: 1541-1552.
15. World Health Organization [WHO] (2012) WHO global tuberculosis report 2012. Geneva: World Health Organization.
16. Lagrange PH, Thangaraj SK, Dayal R, Despande A, Ganguly NK, et al. (2012) A toolbox for tuberculosis diagnosis: an Indian multicentric study (2006-2008): microbiological results. PLoS One 7: e43739.
17. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, et al. (2005) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54: 49-55.
18. Radhakrishna S, Frieden TR, Subramani R, (2003) Association of initial tuberculin sensitivity, age and sex with the incidence of tuberculosis in south India: a 15-year follow-up. Int J Tuberc Lung Dis 7: 1083-1091.
19. World Health Organization (2010) Treatment of Tuberculosis: Guidelines for National Programmes. World Health Organisation.
20. de Beer FC, Nel AE, Gie RP, Donald PR, Strachan AF, (1984) Serum amyloid A protein and C-reactive protein levels in pulmonary tuberculosis: relationship to amyloidosis. Thorax 39: 196-200.
21. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, et al. (2009) Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 9: 162-172.
22. Demir T, Yalcinoz C, Keskinel I, Demiroz F, Yildirim N, (2002) sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 6: 155-159.
23. Chan CH, Lai CK, Leung JC, Ho AS, Lai KN, (1995) Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy. Eur Respir J 8: 70-73.
24. Hosp M, Elliott AM, Raynes JG, Mwinga AG, Luo N, et al. (1997) Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and-seronegative Zambian patients with tuberculosis. Lung 175: 265-275.
25. Immanuel C, Rajeswari R, Rahman F, Kumaran PP, Chandrasekaran V, et al. (2001) Serial evaluation of serum neopterin in HIV seronegative patients treated for tuberculosis. Int J Tuberc Lung Dis 5: 185-190.
26. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, et al. (2005) IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 7: 1-8.
27. Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, et al. (2010) IP-10 detection in urine is associated with lung diseases. BMC Infect Dis 10: 333.
28. Flynn JL, Scanga CA, Tanaka KE, Chan J, (1998) Effects of aminoguanidine on latent murine tuberculosis. J Immunol 160: 1796-1803.
29. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, et al. (1999) Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 115: 110-113.
30. Deveci F, Akbulut HH, Turgut T, Muz MH, (2005) Changes in serum cytokine levels in active tuberculosis with treatment. Mediators Inflamm 2005: 256-262.
31. Lee TS, Chau LY, (2002) Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8: 240-246.
32. Redford PS, Murray PJ, O'Garra A, (2011) The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol 4: 261-270.